CMMB
HEALTHCAREChemomab Therapeutics Ltd
$1.79+0.16 (+9.82%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CMMB Today?
No stock-specific AI insight has been generated for CMMB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.35$5.88
$1.79
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-1.44
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume82K
Avg Volume (10D)—
Shares Outstanding7.2M
CMMB News
20 articles- Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 19, 2026
- Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 17, 2026
- Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of GastroenterologyYahoo Finance·Dec 2, 2025
- Chemomab to Participate in Oppenheimer’s Movers in Rare Disease SummitYahoo Finance·Nov 24, 2025
- Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 20, 2025
- Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing CholangitisYahoo Finance·Nov 6, 2025
- ALKS to Enter Sleep Disorder Market With $2.1B Avadel AcquisitionYahoo Finance·Oct 23, 2025
- SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease StudyYahoo Finance·Oct 22, 2025
- ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock UpYahoo Finance·Oct 17, 2025
- Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in JapanYahoo Finance·Oct 16, 2025
- RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene TherapyYahoo Finance·Oct 15, 2025
- TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key GoalsYahoo Finance·Oct 14, 2025
- CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in InfluenzaYahoo Finance·Oct 10, 2025
- OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study DataYahoo Finance·Oct 10, 2025
- KALA Stock Crashes 88% in a Month Following Eye Disorder Study FailureYahoo Finance·Oct 8, 2025
- AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension StudyYahoo Finance·Oct 8, 2025
- Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 21, 2025
- Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 14, 2025
- Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25Yahoo Finance·Jun 30, 2025
- Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing CholangitisYahoo Finance·Jun 11, 2025
All 20 articles loaded
Price Data
Open$1.63
Previous Close$1.63
Day High$1.84
Day Low$1.63
52 Week High$5.88
52 Week Low$1.35
52-Week Range
$1.35$5.88
$1.79
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-1.44
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume82K
Avg Volume (10D)—
Shares Outstanding7.2M
About Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—